Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. That said, here are three profitable companies to steer clear of and a few better alternatives.

Sotera Health Company (SHC)

Trailing 12-Month GAAP Operating Margin: 32.8%

With a critical role in ensuring the safety of millions of patients worldwide, Sotera Health (NASDAQGS:SHC) provides sterilization services, lab testing, and advisory services to ensure medical devices, pharmaceuticals, and food products are safe for use.

Why Is SHC Not Exciting?

1. Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth
2. Subscale operations are evident in its revenue base of $1.22 billion, meaning it has fewer distribution channels than its larger rivals
3. Weak free cash flow margin of 0.8% has deteriorated further over the last five years as its investments increased

At $19.58 per share, Sotera Health Company trades at 18.8x forward P/E. To fully understand why you should be careful with SHC, check out our full research report (it’s free).

Whirlpool (WHR)

Trailing 12-Month GAAP Operating Margin: 4.2%

Credited with introducing the first automatic washing machine, Whirlpool (NYSE: WHR) is a manufacturer of a variety of home appliances.

Why Are We Out on WHR?

1. Customers postponed purchases of its products and services this cycle as its revenue declined by 7.3% annually over the last five years
2. Sales were less profitable over the last five years as its earnings per share fell by 38.4% annually, worse than its revenue declines
3. High net-debt-to-EBITDA ratio of 9× could force the company to raise capital on unfavorable terms if market conditions deteriorate

Whirlpool is trading at $40.45 per share, or 11.8x forward P/E. Check out our free in-depth research report to learn more about why WHR doesn’t pass our bar.

Integra LifeSciences (IART)

Trailing 12-Month GAAP Operating Margin: 10.6%

Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ: IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.

Why Do We Steer Clear of IART?

1. Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
2. Earnings per share fell by 4.6% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable
3. High net-debt-to-EBITDA ratio of 5× increases the risk of forced asset sales or dilutive financing if operational performance weakens

Integra LifeSciences’s stock price of $16.75 implies a valuation ratio of 6.5x forward P/E. To fully understand why you should be careful with IART, check out our full research report (it’s free).

Stocks We Like More

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.